

Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases

Zhihu Ding,^{4,5,6,9} Chang-Jiun Wu,^{2,4,9} Mariela Jaskelioff,^{4,5,6} Elena Ivanova,⁴ Maria Kost-Alimova,^{2,3,4} Alexei Protopopov,^{2,3,4} Gerald C. Chu,^{4,7} Guocan Wang,^{1,4,5,6} Xin Lu,^{1,4,5,6} Emma S. Labrot,⁴ Jian Hu,^{1,4,5,6} Wei Wang,^{1,4,5,6} Yonghong Xiao,⁴ Hailei Zhang,⁴ Jianhua Zhang,^{2,3,4} Jingfang Zhang,⁴ Boyi Gan,^{4,5,6} Samuel R. Perry,⁴ Shan Jiang,^{1,4} Liren Li,^{2,4} James W. Horner,^{2,3,4} Y. Alan Wang,^{1,4} Lynda Chin,^{2,3,4,8,*} and Ronald A. DePinho^{1,4,5,6,*}

¹Department of Cancer Biology

²Department of Genomic Medicine

³Institute for Applied Cancer Science

University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

⁵Department of Genetics

⁶Department of Medicine

⁷Department of Pathology

⁸Department of Dermatology

Harvard Medical School, Boston, MA 02115, USA

⁹These authors contributed equally to this work

*Correspondence: ichin@mdanderson.org (L.C.), rdepinho@mdanderson.org (R.A.D.)

DOI 10.1016/j.cell.2012.01.039

SUMMARY

To determine the role of telomere dysfunction and telomerase reactivation in generating pro-oncogenic genomic events and in carcinoma progression, an inducible telomerase reverse transcriptase (*mTert*) allele was crossed onto a prostate cancer-prone mouse model null for *Pten* and *p53* tumor suppressors. Constitutive telomerase deficiency and associated telomere dysfunction constrained cancer progression. In contrast, telomerase reactivation in the setting of telomere dysfunction alleviated intratumoral DNA-damage signaling and generated aggressive cancers with rearranged genomes and new tumor biological properties (bone metastases). Comparative oncogenomic analysis revealed numerous recurrent amplifications and deletions of relevance to human prostate cancer. Murine tumors show enrichment of the TGF- β /SMAD4 network, and genetic validation studies confirmed the cooperative roles of *Pten*, *p53*, and *Smad4* deficiencies in prostate cancer progression, including skeletal metastases. Thus, telomerase reactivation in tumor cells experiencing telomere dysfunction enables full malignant progression and provides a mechanism for acquisition of cancer-relevant genomic events endowing new tumor biological capabilities.

INTRODUCTION

Many genome instability mechanisms can contribute to somatic events present in human cancer genomes, particularly epithelial cancers (DePinho, 2000; Storchova and Pellman, 2004). Genetic studies illuminated a key role for telomere dysfunction in driving cancer initiation and shaping cancer genomes (Artandi and DePinho, 2010). When combined with *p53* mutation, which deactivates *p53*-dependent DNA-damage signaling (Chin et al., 1999), telomere dysfunction engenders DNA double-strand breaks that produce nonreciprocal translocations, amplifications, and deletions; this process promotes epithelial carcinogenesis (Artandi et al., 2000; O'Hagan et al., 2002). Telomere dynamics contribute to human epithelial cancers as evidenced by coincidental telomere erosion, anaphase bridging, and chromosomal instability in early stages of carcinogenesis in the colon (Rudolph et al., 2001), prostate (Meeker et al., 2002), breast (Chin et al., 2004), and pancreas (Feldmann et al., 2007). Human carcinoma sequencing has provided additional evidence that a period of telomere dysfunction generates chromosomal rearrangements (Stratton et al., 2009). In human prostate cancer, cancer cells possess shorter telomeres (Sommerfeld et al., 1996) as a result of telomere erosion early in disease evolution (Meeker et al., 2002; Vukovic et al., 2003). Curiously, prostate cancers do not arise spontaneously in mice with telomere dysfunction and *p53* deficiency (Artandi et al., 2000). Although casting uncertainty as to the relevance of telomeres in prostate cancer pathogenesis and in shaping its complex genome, it is also possible that mice may not possess key genetic or environmental factors required to

harness telomere dysfunction as a mechanism to promote the neoplastic process in the prostate.

Whereas telomere dysfunction serves to drive early stages of cancer development, subsequent telomerase activation and restoration of telomere function appear to be critical for full malignant progression. This hypothesis is supported by frequent activation of telomerase in diverse human cancers (Shay and Wright, 2006) and enablement of enforced TERT in oncogene-induced malignant transformation of human primary cells (Hahn et al., 1999). Accordingly, low telomerase activity in normal prostate tissues is markedly elevated in human prostate tumors (Kallakury et al., 1997; Lin et al., 1997; Sommerfeld et al., 1996; Koenen et al., 1998; Zhang et al., 1998).

Genetic events associated with human prostate cancer, the most common cancer and second leading cause of cancer death in American men (Jemal et al., 2010), include *ETS* family member translocation (Tomlins et al., 2005; Rubin, 2008) and (epi)genetic alterations of *PTEN*, *p27^{Kip1}*, *NKX3.1*, *c-MYC*, *FGFRs*, *EZH2*, *MIR101*, *p53*, *SMAD4*, among others (Li et al., 1997; Guo et al., 1997; Abate-Shen et al., 2008; Jenkins et al., 1997; Acevedo et al., 2009; Ding et al., 2011). Genomic analysis of human prostate cancers has revealed numerous recurrent amplifications and deletions (Taylor et al., 2010), pointing to the existence of many new prostate cancer-relevant genes. Identification and validation of these genes in amplifications and deletions are challenged by involvement of a significant fraction of the genome, marked intratumoral heterogeneity, and paucity of human cell-based model systems. In this regard, comparison of human and mouse cancer genomes has proven highly effective in facilitating cancer gene discovery (Kim et al., 2006; Zender et al., 2006), particularly in mouse models with telomere dysfunction that promotes regional amplifications and deletions of cancer-relevant loci (Maser et al., 2007; O'Hagan et al., 2002). Here, we sought to understand the role of telomere dysfunction and telomerase reactivation in prostate cancer progression and in generating genomic events that may promote new tumor biological properties of this common malignancy.

RESULTS

Telomerase Reactivation in Genome-Unstable Mouse Prostate Cancer Model Drives Metastatic Progression

In this study, we employed two distinct *telomerase reverse transcriptase* (*mTert*) alleles to study how telomere dysfunction and subsequent telomerase reactivation influence the genomes and biology of prostate cancer. The first allele is a conventional *mTert* knockout resulting in constitutive telomerase deficiency and telomere dysfunction upon successive generational *mTert*^{-/-} intercrosses. The second allele is a novel inducible *mTert* knockin containing an intronic *Lox-Stop-Lox* cassette (*LSL*) (Figure 1A), and upon Cre-mediated excision of *LSL*, *mTert* is re-expressed under endogenous control mechanisms.

Mice possessing probasin (*PB*) promoter-driven Cre transgene (Wu et al., 2001) and *p53/pten* conditional knockout alleles (hereafter *PB-Pten/p53*) characteristically develop locally invasive nonmetastatic prostate adenocarcinoma with high penetrance and short latency (Chen et al., 2005). Alleles were backcrossed a minimum of four generations onto C57Bl/6.

Upon successive generational intercrosses of *LSL-mTert* mice, late generations show classical constitutional signs of telomere dysfunction, including reduced body weight (Figure 1D), widespread organ atrophy (Figures 1B and 1E), diminished proliferation, and increased apoptosis in highly proliferative tissues (Figures 1C and 1F), among other phenotypes as reported previously (Lee et al., 1998). Of note, *PB-driven Cre* expression is restricted to prostate epithelium and becomes active at sexual maturity. Thus, Cre-mediated deletion of *LSL* and *mTert* re-expression (telomerase reactivation) can occur in prostate epithelium experiencing telomere dysfunction.

PB-Pten/p53 alleles were carried through successive generational mating of *LSL-mTert* mice (Figure S1 available online), generating "telomere-intact" controls (*wild-type* and *LSL-mTert* heterozygous mice, designated "G0 *PB-Pten/p53*") and "telomere dysfunctional" experimental mice (third and fourth generation *LSL-mTert*, designated "G3/4 *LSL-mTert PB-Pten/p53*"). In parallel, we generated control and experimental cohorts of *PB-Pten/p53* mice harboring the conventional *mTert* null allele (*mTert*^{-/-}) (Farazi et al., 2006), producing analogous G3/4 *mTert*^{-/-} *PB-Pten/p53* to study the impact of telomere dysfunction only.

Consistent with a previous report (Chen et al., 2005), G0 *PB-Pten/p53* mice with *mTert*^{+/+} or *mTert*^{+/-} alleles (i.e., without telomere dysfunction) developed rapidly progressive, locally invasive prostate adenocarcinomas with 100% penetrance, whereas G3/4 *mTert*^{-/-} *PB-Pten/p53* mice (i.e., experienced ongoing genome instability due to telomere dysfunction) had smaller, poorly progressive tumors (Figures 2A–2D). Serial histological analyses revealed high-grade prostate intraepithelial neoplasia (HPIN) by age 9 weeks in both cohorts (Figure S2A). However, most G3/4 *mTert*^{-/-} *PB-Pten/p53* tumors failed to progress beyond HPIN through age 24 weeks (Figures 2C and 2D; Table S1), whereas G0 *PB-Pten/p53* tumors evolved to invasive adenocarcinoma by age 24 weeks with 100% penetrance (Figures 2C and 2D). In comparison, G3/4 *LSL-mTert PB-Pten/p53* mice (i.e., experienced baseline telomere dysfunction prior to telomerase reactivation at sexual maturity) also initiated with HPIN by age 9 weeks (Figure S2A), but unlike the G3/4 *mTert*^{-/-} mice, they developed bulky lethal tumors by age 24 weeks (Figures 2A–2D). These observations reinforced the established role of telomere dysfunction in facilitating cancer initiation yet constraining full malignant progression (Rudolph et al., 2001; González-Suárez et al., 2000; Chin et al., 1999), whereas telomerase reactivation enabled rapidly progressive disease. Importantly, a new phenotype emerged among some of the G3/4 *LSL-mTert PB-Pten/p53* mice that is not observed in the genome-stable G0 *PB-Pten/p53* mice, namely lumbar spine metastases (5/20, 25%) (Figures 2E, 2F, and S2B). The prostate cancer origin of these metastases was confirmed by genotype analysis of Cre-deleted *Pten*, *p53*, and *LSL* sequences (Figures S2C and S2D; not shown). This new phenotype suggests that its evolution requires not just a stable genome but antecedent instability induced by telomere dysfunction.

Next, the impact of telomerase reactivation was assessed in age-matched prostate tumors from each model. Quantitative telomere-fluorescence in situ hybridization (FISH) revealed decreased telomere reserves in G3/4 *mTert*^{-/-} *PB-Pten/p53*




Figure 1. A Novel Inducible *mTert* Knockin Containing an LSL Cassette in the First Intron

(A) LSL-*mTert* knockin strategy. PB-Cre4-redirected, Cre-mediated recombination removes the LSL cassette in prostate epithelium to restore endogenous *mTert* expression.

(B and C) Later generations (G3, G4) of *mTert*^{-/-} PB-Pten/p53 (panel b) or LSL-*mTert* PB-Pten/p53 alleles (panel c) displayed telomere dysfunction as demonstrated by decreased testis weight, compared to G0 *mTert* PB-Pten/p53 (panel a) (B), and increased apoptotic bodies in intestine (C).

(D–F) Quantification of body weight (D), testis weight (E), and apoptotic bodies per 100 intestinal crypts (F) of G0 PB-Pten/p53 (denoted as G0 *mTert*) (n = 20), G3/4 *mTert*^{-/-} PB-Pten/p53 (denoted as G4 *mTert*^{-/-}) (n = 31), and G3/4 LSL-*mTert* PB-Pten/p53 (denoted as G3/4 LSL-*mTert*) (n = 20) mice (F). Error bars represent standard deviation (SD), * indicates p < 0.05.

See also Figure S1.

samples relative to G0 PB-Pten/p53 samples, whereas G3/4 LSL-*mTert* PB-Pten/p53 samples showed longer telomere lengths relative to G3/4 *mTert*^{-/-} PB-Pten/p53 (Figure S3). As eroded dysfunctional telomeres generate a DNA-damage response (Takai et al., 2003; d'Adda di Fagagna et al., 2003),

functional restoration of telomeres was assessed by examination of DNA-damage signaling (p53BP1 foci) in the various models. Strong anti-p53BP1 signal was detected in G3/4 *mTert*^{-/-} PB-Pten/p53 tumor cells and was greatly reduced in G0 PB-Pten/p53 and G3/4 LSL-*mTert* PB-Pten/p53 tumor cells




Figure 2. Telomere Dysfunction and Telomerase Impact Prostate Cancer Progression

(A) Gross anatomy of representative prostates at 24 weeks of age.

(B) Quantification of the prostate tumors of G0 *mTert* (n = 20), G3/4 *mTert*^{-/-} (n = 31), and G3/4 *LSL-mTert* (n = 20) mice. Error bars represent SD.

(C) Representative H&E sections of the prostate tumors from G0 *mTert* (panel a), G3/4 *mTert*^{-/-} (panel b), and G3/4 *LSL-mTert* (panel c) mice at 24 weeks of age.

(D) Quantification of locally invasive prostate tumors of G0 *mTert* (n = 20), G3/4 *mTert*^{-/-} (n = 31), and G3/4 *LSL-mTert* (n = 20) mice at 24 weeks of age.

(E) H&E sections of the prostate tumors of G4 *LSL-mTert* in spinal bone at 24 weeks of age.

(F) Quantification of prostate tumors with spread lumbar spine in G0 *mTert* (n = 20), G3/4 *mTert*^{-/-} (n = 31), and G4 *LSL-mTert* (n = 20) mice.

See also Figure S2 and Table S1.

(Figures 3A and 3B; n = 3 each). Correspondingly, there was markedly increased apoptosis and decreased proliferation in G3/4 *mTert*^{-/-} *PB-Pten/p53* tumor cells compared with G0 *PB-Pten/p53* and G3/4 *LSL-mTert PB-Pten/p53* controls (Figures 3C–3E). Thus, telomerase activation alleviates telomere dysfunction checkpoints in G3/4 *LSL-mTert PB-Pten/p53* cancers.

Taken together, the molecular and phenotypic characterization of these three models demonstrated that telomerase reactivation not only enables the bypass of the progression block conferred by telomere dysfunction by quelling the DNA-damage signals but also engenders the acquisition of new tumor biological properties (bony tumor growth) not observed in tumors that

did not experience a period of telomere dysfunction with subsequent telomerase reactivation in their evolution. This thus provides the first genetic evidence that telomerase reactivation and genome stabilization are necessary to drive full malignant progression in epithelial cancers.

Genome Stabilization by Telomerase Reactivation Selects for Copy Number Aberrations of Human Relevance

We hypothesized that baseline telomere dysfunction in G3/4 *LSL-mTert PB-Pten/p53* cells followed by telomerase reactivation in the prostate upon sexual maturity at 5–7 weeks of age (Chen et al., 2005; Wu et al., 2001) would be permissive of the




Figure 3. Telomerase Reactivation Maintains Telomere Length and Allows Tumor Cells to Proliferate

(A) Strong telomere dysfunction-induced p53BP1 foci were presented in G3/4 *mTert*^{-/-} cells (panel b) but not in G4 *LSL-Tert* cells (panel c).

(B) Quantification of p53BP1-positive prostate tumor cells. Error bars represent SD for a representative experiment performed in triplicate.

(C–E) Telomere dysfunction-induced apoptosis and blockage of proliferation. Quantification of TUNEL-positive (C), caspase-3 activation-positive (D), and Ki67-positive prostate tumor cells (E). Error bars represent SD for a representative experiment performed in triplicate.

See also Figure S3.

accumulation of genomic events in established tumors. Indeed, spectral karyotyping (SKY) analyses of G0 *PB-Pten/p53* and G3/4 *LSL-mTert PB-Pten/p53* prostate tumors revealed an increased number of chromosomal structural aberrations in G3/4 *mTert LSL-mTert PB-Pten/p53* tumor samples ($n = 5$) relative to G0 *PB-Pten/p53* controls ($n = 4$) (Figures 4A–4C; 3.2 versus 1.0 per 100 chromosomes, respectively, $p < 0.05$, t test). These cytogenetic aberrations included multicentric chromosomes, nonreciprocal translocations (NRTs), in addition to p-p, p-q, and q-q chromosome arm fusions involving homologous and/or nonhomologous chromosomes (Figure 4B).

Telomere dysfunction and the associated bridge-fusion-breakage process are known to create DNA double-strand breaks, leading to regional amplifications and deletions at the sites of breakage (O'Hagan et al., 2002). Under biological selection, this process can result in copy number aberrations (CNAs) at cancer-relevant loci (Maser et al., 2007; O'Hagan et al., 2002). Prompted by this, we performed array-based CGH and transcriptional profile analyses of 18 G3/4 *LSL-mTert PB-Pten/p53* tumors. Compared to matched germline DNA in each case, 94 recurrent somatic copy number alterations (sCNAs) were defined by MCR analysis, encompassing 2,183 amplified and 3,531 deleted genes (Figure S4; Table S2).

To assess human relevance of these murine sCNAs, we used GISTIC2 (Beroukhi et al., 2007) to analyze genome-wide copy

number profiles of 194 human prostate tumors (Taylor et al., 2010); this defined 55 recurrent focal sCNAs and 10 recurrent chromosomal arm-level gains or losses (Figure S4). Cross-species comparisons by orthologs revealed that 22 of the 94 murine sCNAs harbored synteny to either focal or broad sCNAs in humans. Consistent with previous studies, resident genes (300 amplified genes and 441 deleted genes) in these syntenic sCNAs were indeed significantly enriched for cancer-relevant genes (Figure S4; Table S2). In particular, one of the cross-species-conserved CNAs involving mouse chromosome 15 and human chromosome 8 was notable for high recurrence in both species (mouse: 12/18, 67% and human: 43/194, 22%) (Table S2; Figure 4D). This syntenic region contains the prostate cancer-relevant *MYC* oncogene as well as other known cancer genes not previously implicated in prostate cancer, such as WNT pathway regulator *FDZ6* (Table S2).

Recognizing that not all genes resident in sCNAs are drivers, we next implemented a series of integrative analyses (as outlined in Figure S4) designed to cull passengers. Briefly, for genes resident in regions of syntenic amplifications or gains, we prioritized those with copy number-correlated expression in mouse and human samples; for genes in regions of loss, we prioritized those with nonsynonymous mutations documented in COSMIC or in NCBI PubMed, as well as evidence of promoter DNA hypermethylation in the published literature (Forbes et al., 2011; Ongenaert et al.,




Figure 4. Oncogenomic Alterations that Occur in G3/4 *LSL-mTert* Prostate Tumors

(A) Representative SKY images from metaphase spreads from G0 (panel a) and G3/4 (panel b) prostate tumors.

(B) Quantification of cytogenetic aberrations (recurrences) detected by SKY in G0 *mTert* (n = 4) and G3/4 *LSL-mTert* (n = 5) prostate tumors. Error bars represent SD.

(C) Quantification of cytogenetic aberrations (recurrences) detected by SKY in G0 *mTert* (green) and G3/4 *LSL-mTert* (purple) prostate tumors.

(D) Recurrence plot of CNAs defined by aCGH for 18 mouse prostate tumors. The x axis shows the physical location of each chromosome. The percentage of prostate tumors harboring gains (bright red, $\log_2 > 0.6$), losses (green, $\log_2 < -0.3$), and deletions (dark green, $\log_2 < -0.6$) for each locus is depicted.

See also Figure S4 and Tables S2 and S3.

2008). Furthermore, we posit that drivers targeted by sCNAs with functional consequences are more likely to be selected for during progression. Thus, we utilized the expression profile data in metastatic versus primary tumors from six prostate cancer cohorts on Oncomine (Lapointe et al., 2004; LaTulippe et al., 2002; Vanaja et al., 2003; Varambally et al., 2005; Yu et al., 2004; Holzbeierlein et al., 2004) to define the subset of genes exhibiting a progression-correlated expression pattern in human; namely, genes resident in regions of loss in the mouse tumors are downregulated in human metastases compared to primary, or conversely genes in regions of gains are upregulated in human metastases. This multidimensional integrative analysis narrowed our cross-species-conserved gene list down to 228 genes (77 amplified and 151 deleted) (Figure S4; Table S3).

TGF- β /Smad4 Pathway in Prostate Tumors with Bone Metastasis

As a first step to identify molecular events capable of driving metastasis to the bone, we asked whether a subset of the above

228 candidate genes are subjected to consistent amplification/deletion in the 14 bone metastases in the cohort reported by Taylor et al. (2010). Specifically, we interrogated each of the 77 amplified or 151 deleted candidates for evidence that it is more likely to be amplified or deleted in bone metastasis, respectively. The resultant 113 gene list (comprising 37 amplified and 76 deleted genes associated with bone metastasis) was then enlisted into knowledge-based pathway analysis. Interestingly, TGF- β signaling genes represented the most significantly enriched network among the nine significant pathways with false discovery rate (FDR) < 0.1 (Table S4; Figure S5A). Corroborating with this pathway analysis result is the observation that *Smad4* is encompassed by genomic loss in 2 of the 18 (11%) G3/4 *LSL-mTert* PB-Pten/p53 tumor genomes, suggesting that TGF- β signaling and *SMAD4* specifically may be targeted during prostate cancer skeletal metastasis. This is consistent with recent reports on the pathogenetic and prognostic roles of *SMAD4* in human prostate cancer (Ding et al., 2011) and its frequent epigenetic silencing in advanced disease (Aitchison et al., 2008).




Figure 5. Codeletion of *SMAD4* together with *PTEN* and *p53* Leads to Aggressive Prostate Cancer Progression

(A and B) Log₂ ratio of array-CGH plots showing conserved deletion of *SMAD4* in both mouse G3/4 LSL-*mTert* tumor (A) and human prostate tumor samples (B). The y axis shows log₂ of copy number ratio (normal, log₂ = 0); amplifications are above and deletions are below this axis; x axis is chromosome position, in Mbp. (C and D) Log₂ ratio of array-CGH plots showing codeletion of *PTEN* (C) and *p53* (D) in that same human prostate sample with the *SMAD4* deletion. (E) Codeletion analysis of *PTEN*, *p53*, and *SMAD4* in human prostate cancer samples (n = 194). The p value (Fisher's exact test) = 2.9×10^{-6} (asterisk). (F) Survival curves showing significant decrease in life span in *PB-Pten/p53/Smad4* (n = 24) (asterisk) compared with *PB-Pten/p53* (n = 25) or *PB-Pten/Smad4* (n = 44) cohorts by Kaplan-Meier overall cumulative survival analysis (p < 0.0001). (G) H&E sections of prostate tumors of *PB-Pten/p53/Smad4* in spinal bone at age 19 weeks. See also Figure S5 and Table S4.

To genetically validate the above hypothesis, we crossed a prostate-specific *PB* promoter-driven *Smad4* conditional knockout allele onto the prostate-specific *p53/Pten* double null model (*PB-p53/Pten*). The rationale for using the prostate-specific *p53/pten* knockout model is based on the fact that this mouse model does not develop bone metastasis, and, in human prostate cancers (Taylor et al., 2010), loss of *SMAD4* as part of a large regional CNA is frequent (18% = 35/194) and often co-occurs with *p53* and *PTEN* loss (Figures 5B–5D) (Figure 5E, p = 2.9×10^{-6} by Fisher's exact test). Consistent with the genomic data, prostate-specific deletion of all three tumor suppressors led to a more aggressive tumor phenotype and shorter overall survival. The median survival time of 17.05 weeks in *Pten/p53/Smad4* was significantly shorter than in *Pten/p53*

(26.3 weeks) or *Pten/Smad4* (22.8 weeks) models (Figure 5F; p < 0.0001, log-rank test). Most importantly, 3/24 (12.5%) of the triple knockout mice developed spontaneous bone metastasis (Figure 5G).

In summary, pathway analysis of the cross-species-conserved gene list triangulated with the biological phenotype in human prostate cancers led to the hypothesis that TGF- β /SMAD4 signaling is an important driver of bone metastasis in the context of *Pten* and *p53* deficiencies. Utilizing the combined *Pten/p53/Smad4* GEM model, we demonstrate the new tumor biological properties (skeletal metastases) of this GEM model are not present in *Pten/p53* or *Pten/Smad4* telomere-intact GEM models. This study establishes, in a genetic manner, that telomerase reactivation in tumor cells experiencing telomere

dysfunction provides a mechanism for selection of cooperative events required to progress fully and manifest the tumor biological properties governed by such genomic events.

Evolutionarily Conserved, Genomically Altered Genes Correlating with Bone Metastasis Are Prognostic in Human

The *in vivo* genetic experiment above proving a driver role for *Smad4* in bone metastasis suggests that additional genes on our bone metastasis-associated gene list may have functional importance as well. As *SMAD4* has also been shown to carry prognostic significance (Ding et al., 2011), we reasoned that prognostic relevance may serve as a surrogate for biological importance. As a proof of concept, we focused on the 14 genes that are represented in the 9 pathways found to be significantly enriched in the bone metastasis-associated gene list (Table S4). Specifically, we assessed how robustly these 14 genes can stratify risk for biochemical recurrence (BCR, defined by post-surgery PSA > 0.2 ng/ml) among the 140 patients with outcome annotation (Taylor et al., 2010). Gratifyingly, the overall risk score based on the 14 gene signature was significantly prognostic of BCR with a hazard ratio of 13 (p value < 10^{-14} , overall C index = 0.93, see Figure S5B) by multivariate Cox regression analysis. Further support for these 14 genes as likely drivers of bone metastasis phenotype derived from the observation that they provided independent prognostic value to the previously reported 4 gene signature (comprising *PTEN/SMAD4/CCND1/SPP1*) derived from the *Pten/Smad4* model (Ding et al., 2011), consistent with the fact that bone metastasis was not observed in the *Pten/Smad4* GEM model (hazard ratio = 8.7, p = 2.16×10^{-13} , and overall C index = 0.93, see Figure S5C). In particular, combination of the 14 gene with the 4 gene signature increases the predictive power of either gene set alone (hazard ratio = 20, p < 10^{-14} , and overall C index = 0.96, see Figure S5D).

Taken together, the prognostic correlation of these 14 genes represented in the 9 functional pathways enriched in the bone metastasis-associated gene set provides the correlative evidence for biological relevance of these genes to human prostate cancers, although their individual contribution and mechanism of action will require further exploration. Additionally, these results serve as validation of the integrative approaches adopted by this study, which leverages the clear genotype-phenotype correlation in model systems with the power of genomic and bioinformatic analyses to elucidate molecular mechanisms driving bone metastasis in human prostate cancers.

DISCUSSION

We explored the role of telomere dysfunction and telomerase reactivation in shaping the genomes and impacting the biology of prostate cancer. These genetic studies *in vivo*, together with human and mouse prostate cancer genomic data, provide evidence that telomere dysfunction plays a critical role in prostate cancer initiation and progression, permitting acquisition of and selection for cancer-relevant genomic events upon telomerase reactivation. In addition, our studies support the idea that telomere dysfunction and subsequent telomerase activation enable evolving cancers to progress fully and acquire new tumor

biological properties including cardinal features of advanced human prostate cancer.

Finally, comparative oncogenomic analysis of gene copy number and expression profiles with genotype-phenotype correlation resulted in identification of genes associated with progression to bone metastasis, highlighting the potential utility of this integrative approach for cancer gene discovery in prostate cancer.

Previous telomere and cytogenetic studies have documented chromosomal instability and telomere loss in early stage human prostate cancers (Sommerfeld et al., 1996; Meeker et al., 2002; Vukovic et al., 2003), implicating this mechanism in driving chromosomal instability and intratumoral heterogeneity in these emerging malignancies. These findings, along with work in the telomerase knockout mouse model (Artandi and DePinho, 2010), support a model where telomere dysfunction provides a mechanism fueling the early acquisition of somatic genomic events in prostate cancer as well as other epithelial cancers. Consistent with previous work in other epithelial cancers, we observed that constitutive telomere dysfunction in the G3/4 *mTert*^{-/-} *PB-Pten/p53* model enabled cancer initiation; however, these malignancies exhibited a constrained progression phenotype that was associated with activation of DNA-damage signaling and increased apoptosis and decreased proliferation. Together, these data suggest that although telomere dysfunction may enable cancer initiation, ongoing telomere dysfunction and cellular checkpoints impede full malignant progression of HPIN to invasive and metastatic disease, and that activation of telomere maintenance mechanisms may be needed to quell both rampant chromosomal instability and residual cellular checkpoints. In this regard, it is notable that there is no discernable inhibition in the progression from HPIN to invasive disease in G2 *mTert*^{-/-} *PB-Pten/p53* mice that do not express telomerase yet maintain adequate telomere reserves (data not shown). These data establish that telomerase activity per se is not essential for prostate cancer progression, providing tumor cells possess functional telomeres. Correspondingly, current cell-based evidence in human and mouse systems, together with the consistent expression of telomerase in human prostate cancers (Kallakury et al., 1997; Lin et al., 1997; Sommerfeld et al., 1996; Koeneman et al., 1998; Zhang et al., 1998), supports the view that telomerase reactivation plays a critical role in overcoming apoptotic and proliferative blocks needed for full malignant progression (Chang et al., 2003; Hahn et al., 1999; Chin et al., 1999).

Here, our inducible telomerase model system enabled genetic analysis of the impact of physiological endogenous telomerase reactivation in a naturally arising solid tumor with short dysfunctional telomeres. These studies established that telomerase reactivation enabled rapidly progressive disease in all cases. At the same time, we established that antecedent telomere dysfunction enabled the acquisition of genomic events, including those capable of endowing tumors with new biological properties such as bone metastasis, a phenotype not observed in G0 *PB-Pten/p53* tumors (telomere intact). Thus, we conclude that a period of telomere dysfunction is a mechanism for the development of chromosomal aberrations targeting genes involved in prostate cancer development including bone metastasis.

The recurrent nature of amplifications and deletions of human prostate cancer raised the possibility that, along with a handful of known genetic lesions, there remain many uncharacterized genes governing genesis and progression of this cancer (Taylor et al., 2010). Beyond restoring genome stability and eliminating DNA-damage signals, we and others have shown that genomic alterations acquired in genome-unstable mouse tumor genomes are not random, as they show statistical significant overlap between mouse (which is telomerase deficient/unstable) and human (which is telomerase reactivated) (Maser et al., 2007). This observation leads us to hypothesize that reactivation of telomerase in the setting of pre-existing genome instability can be a genomic mechanism for selection of cooperative events required for ultimate progression—in other words, it is not merely a permissive step by removing DNA damage, but telomerase reactivation is instead an active driver of progression. This study provides formal genetic proof for this thesis. By triangulating the list of genes resident in syntenic sCNAs in mouse and human prostate cancers with biological phenotypes in human (e.g., documented bone metastasis), we have defined a prioritized list of bone metastasis-associated genes. Pathway analysis with this list revealed that the dominance of the TGF- β /SMAD4 network, coupled with the observation of spontaneously acquired *Smad4* genomic loss in two of the mouse tumors, led to the hypothesis that *SMAD4* inactivation is a driver for bone metastasis in prostate cancers. Again, leveraging the power of genetic engineering in the mouse, we went on to perform the definitive genetic validation experiment proving the cooperativity of *p53/Pten/Smad4* codeletion in driving prostate tumorigenesis and progression to bone metastasis in vivo.

It is, however, important to note that the penetrance of bone metastasis in mice with triple inactivation of *p53/Pten/Smad4* was far from 100%, suggesting that additional events beyond *Smad4* in the tumor and/or stromal cells can drive or are required for bone metastasis. Indeed, many other candidates with likely relevance have also been identified through our cross-species comparative oncogenomic analysis. For example, among the amplified genes, several have been implicated in cancer progression. Metadherin (*MTDH*), a gene with dual activity to promote metastasis and chemoresistance (Hu et al., 2009), is overexpressed in human prostate cancer and known to act as an activator of AKT and a suppressor of FOXO3a (Kikuno et al., 2007). Protein tyrosine kinase 2 (*PTK2*, a.k.a., *FAK*), a gene located in the frequently amplified 8q24 region, is well known for its role in cell motility and proliferation (Chang et al., 2007) and in promoting human prostate cancer cell invasiveness (Johnson et al., 2008). Notable deleted genes include *APC* (20% in human prostate cancer, 11% in mouse prostate cancer) and *Smad2/Smad4* (20% in human prostate cancer, 11% in mouse prostate cancer), highlighting the importance of activation of the Wnt signaling pathway and deactivation of the TGF- β pathway in prostate cancer progression (Ding et al., 2011).

Lastly, because it is not likely that all of the evolutionarily conserved candidates identified in this study represent true drivers of prostate cancer progression in human, definitive demonstration of biological activity and elucidation of mechanisms of action for each will require significant downstream activities by many. On the other hand, the prognostic signifi-

cance of the 14 pathway-representative genes is a strong correlative support for functional veracity of the candidate list, even though we recognize that BCR is only a surrogate for aggressiveness of human prostate cancers. Further prognostic studies for lethality will be necessarily to validate the true utility of the 14 gene signature in human.

In summary, this study provides in vivo genetic evidence confirming the long-held hypothesis that telomerase reactivation quells DNA-damage signaling and stabilizes the genome of an initiated cancer to permit cancer progression. This study also provides evidence in naturally occurring and initiated cancer in vivo that telomere dysfunction followed by telomerase reactivation serve as a mechanism for the generation of and selection for cancer-relevant genomic alterations to drive progression and new tumor biological hallmarks such as metastasis to bone. Thus, telomerase serves as an active driver of cancer progression in the setting of telomere-based crisis. Furthermore, the validation of telomere dysfunction as a relevant genome instability mechanism in prostate cancer, the generation of highly rearranged genomes with syntenic events, and the in silico documentation that altered genes are enriched for cancer relevance collectively provide a system to enhance the mining of complex human prostate cancer genomes to identify genetic events governing prostate cancer progression.

EXPERIMENTAL PROCEDURES

mTert Knockout Allele and *Pten* and *Trp53* (*p53*) Conditional Alleles

The *mTert* knockout allele and the *Pten*^{loxP} conditional knockout alleles have been described elsewhere (Zheng et al., 2008; Farazi et al., 2006). The *p53*^{loxP} strain was generously provided by A. Berns (Marino et al., 2000). Prostate epithelium-specific deletion was effected by the *PB-Cre4* (Wu et al., 2001) and was obtained from MMHCC (http://mouse.ncicrf.gov/search_results.asp).

Generation of the *LSL-mTERT*^{loxP} Allele

We knocked an *LSL* cassette into the first intron of the mouse *Tert* gene (Figure 1A). The presence of the *LSL* cassette produces a null *mTert* allele, and its removal by *PB-Cre* expression restores activity under the control of the native *mTert* promoter. This mouse model scheme allows for excellent specific control of telomerase reconstitution in prostate epithelia cells. Following introduction of the knockin construct into embryonic stem cells (ESCs), screening ESCs, confirming germline transmission, and *NeoR* cassette deletion via *Ella-Cre*, the *LSL-mTert* allele was backcrossed four generations onto the C57Bl/6 background.

Mating Scheme

As depicted in Figure S1, the *LSL-mTert*^{L/+} *p53*^{L/L} *Pten*^{L/L} mice were crossed with G0 *mTert*^{+/-} *p53*^{L/L} *Pten*^{L/L} *PB-Cre4* mice to generate G0 *mTert*^{+/-} *p53*^{L/L} *Pten*^{L/L} *PB-Cre4*, G0 *LSL-mTert*^{L/+} *p53*^{L/L} *Pten*^{L/L} *PB-Cre4*, G1 *mTert*^{-/-} *LSL-mTert*^{L/+} *p53*^{L/L} *Pten*^{L/L} *PB-Cre4*, and G1 *mTert*^{-/-} *LSL-mTert*^{L/+} *p53*^{L/L} *Pten*^{L/L} mice. These mice were then intercrossed to generate G2 *mTert*^{-/-} *p53*^{L/L} *Pten*^{L/L} *PB-Cre4*, G2 *mTert*^{-/-} *LSL-mTert*^{L/+} *p53*^{L/L} *Pten*^{L/L} *PB-Cre4*, G2 *LSL-mTert*^{L/+} *p53*^{L/L} *Pten*^{L/L} *PB-Cre4*, G2 *mTert*^{-/-} *p53*^{L/L} *Pten*^{L/L}, G2 *mTert*^{-/-} *LSL-mTert*^{L/+} *p53*^{L/L} *Pten*^{L/L}, G2 *LSL-mTert*^{L/+} *p53*^{L/L} *Pten*^{L/L}. G2 mice were then intercrossed to generate G3 and G4 mice.

Tissue Analysis

Normal and tumor tissues were fixed in 10% neutral-buffered formalin overnight, then processed, paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E) according to standard protocol. Immunohistochemistry analysis was done as previously described (Ding et al., 2011). Antibodies used for IHC include anti-Ki67 (Dako), anti-53BP1 (Bethyl Labs), and anti-Cleaved Caspase 3 (Cell Signaling). Cells with the 53BP1 nuclear

punctuate foci were considered as 53BP1 positive, whereas the absence of 53BP1 nuclear foci signal was considered 53BP1 negative. Western blot analysis was done as previously described (Ding et al., 2011).

Laser Capture Microdissection and DNA Extraction

Laser capture microdissection was done as previously described (Emmert-Buck et al., 1996). Genomic DNA of microdissected prostate tumor cells was extracted with phenol-chloroform prior to PCR analysis.

TUNEL Assay

To determine apoptosis in prostate tumor cells, TUNEL staining was performed as previously described (Ding et al., 2011).

Cytogenetics, Quantitative Telomere-FISH, and Spectral Karyotyping Analysis

We prepared metaphase chromosomes from early passage prostate tumor cells as previously described (Maser et al., 2007).

Establishment of Mouse Prostate Tumor Cell Lines

Tumors were dissected from prostates of G0 *Pten*^{L/L} *Trp53*^{L/L} *PB-Cre4*⁺, G3, and G4 mice. Cell lines were established as described previously (Ding et al., 2011).

RNA Isolation and Real-Time PCR

Total RNA was extracted and real-time PCR were done as previously described (Ding et al., 2011).

Array-CGH Profiling and Analysis of Mouse Prostate Tumors

Murine G3/4 *LSL-mTert PB-Pten/p53* tumors were profiled against matched normal tail DNA. Labeled DNAs were hybridized onto Agilent mouse 244K CGH arrays, and scanning was performed per manufacturer's protocol. Data were processed using Agilent software. The array-CGH data of 18 G3/4 *LSL-mTert PB-Pten/p53* tumors were analyzed with the MCR algorithm (Maser et al., 2007) to detect focal genomic regions with CNA events in at least two tumors. Mouse genome data build mm9 was used in the analysis. A total of 2,183 genes from 57 amplified regions (Table S2) and 3,531 genes from 38 deletion regions were detected by the MCR algorithm.

Array-CGH Analysis with the GISTIC2 Algorithm for Recurrent Focal and Arm-Level Chromosomal CNAs in Human Prostate Tumors

The array-CGH data of 194 human prostate tumors (Taylor et al., 2010) were analyzed with the GISTIC2 algorithm (Beroukhi et al., 2007) to detect focal genomic regions with CNA events. Focal regions with *q* values smaller than 0.25 are considered significant, which resulted in 16 amplified and 39 deleted regions. Arm-level changes with *q* values smaller than 0.005 are considered significant, which suggested chromosome 7p, 7q, and 8q amplification and 6q, 8p, 12p, 13q, 16q, 17p, and 18q deletion.

Homolog Mapping for CNA Synteny Regions Crosses Human and Mouse Tumors

We used the NCBI homogene database (version 39.2) to map human and mouse homolog genes and detect synteny CNA regions. The homogene analysis characterized 300 amplified genes and 441 deleted genes that commonly recurred in human and mouse prostate tumors.

Codeletion Analysis in Human Clinical Samples

Based on the results of the GISTIC2 analysis, 194 human prostate tumors (Taylor et al., 2010) were classified into 4 groups according to *PTEN* and *p53* focal deletion status (Figure 5E). The numbers of *SMAD4* deletion events in each group were used to estimate by Fisher's exact test in R environment the significance *p* value of codeletion enrichment.

Correlation Analysis between Gene Copy Numbers and Gene Expression Changes

The Spearman correlation coefficients between individual gene copy numbers and expression levels in matching samples were calculated in R environment. *p* values less than 0.05 were considered significant.

Oncomine Consensus Analysis

Six prostate cancer cohorts (Holzbeierlein et al., 2004; Lapointe et al., 2004; LaTulippe et al., 2002; Vanaja et al., 2003; Varambally et al., 2005; Yu et al., 2004) in the Oncomine database (<http://www.oncomine.com>) were used to filter our candidate marker gene lists. We tested the following hypotheses: whether genes in the amplified regions are related to metastatic phenotypes in any of the six cohorts, or whether genes in the deleted regions are related to indolent phenotypes in any of the six cohorts.

Bone Metastasis-Related Copy Number Changes

We tested whether genes recurrently amplified or deleted in the whole prostate cancer cohort of Taylor et al. showed consistent CNA patterns in tumors with documented bone metastasis (Taylor et al., 2010). For each candidate gene, we counted the numbers of gene gain (copy number > 0.3 in log₂ scale) and loss (copy number < -0.3 in log₂ scale) in 14 bone metastasis tumors. Consistent changes are defined if an amplified CNA gene is more likely to have gain than loss or a deleted CNA gene more likely to be lost than gained in bone metastatic tumors.

Survival Analysis

We applied Cox proportional hazard regression on biomarkers of interest to get a multivariate linear regression model that best predicts the biochemical recurrence of prostate cancer. Tumors were subsequently divided into high-risk and low-risk groups according to the scores. Kaplan-Meier curves were plotted by R software, and the statistical significance was estimated by log-rank test.

ACCESSION NUMBERS

Microarray and aCGH data were deposited in GEO (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35247>) under the accession number GSE35247.

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and four tables and can be found with this article online at doi:10.1016/j.cell.2012.01.039.

ACKNOWLEDGMENTS

We thank S. Zhou and J.P. Morin for excellent mouse husbandry and care, J. Paik, M. Kim, and H. Ying for helpful discussion. We thank W. Hahn for shRNA constructs. Z.D. was supported by the Damon Runyon Cancer Research Foundation. Y.A.W. was supported by the Multiple Myeloma Research Foundation. This work is supported by NCI R01CA084628 (R.A.D.), U01CA141508 (L.C. and R.A.D.), the Prostate Cancer Foundation (R.A.D. and Z.D.), and DOD W81XWH-07-PCR-IDA (R.A.D. and Z.D.). R.A.D. was an American Cancer Society Research Professor and supported by the Robert A. and Renee E. Belfer Foundation. The gene signature and technology developed in this paper have been licensed by Metamark GENETICS (<http://www.metamarkgenetics.com/>). L.C. and R.A.D. are the founders of Metamark GENETICS. Z.D. and C.J.W. are consultants for Metamark GENETICS.

Received: July 2, 2011

Revised: November 9, 2011

Accepted: January 25, 2012

Published online: February 16, 2012

REFERENCES

- Abate-Shen, C., Shen, M.M., and Gelmann, E. (2008). Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. *Differentiation* 76, 717–727.
- Acevedo, V.D., Ittmann, M., and Spencer, D.M. (2009). Paths of FGFR-driven tumorigenesis. *Cell Cycle* 8, 580–588.

- Aitchison, A.A., Veerakumarasivam, A., Vias, M., Kumar, R., Hamdy, F.C., Neal, D.E., and Mills, I.G. (2008). Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. *Prostate* 68, 661–674.
- Artandi, S.E., and DePinho, R.A. (2010). Telomeres and telomerase in cancer. *Carcinogenesis* 31, 9–18.
- Artandi, S.E., Chang, S., Lee, S.L., Alson, S., Gottlieb, G.J., Chin, L., and DePinho, R.A. (2000). Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. *Nature* 406, 641–645.
- Beroukhi, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, L., Lee, J.C., Huang, J.H., Alexander, S., et al. (2007). Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proc. Natl. Acad. Sci. USA* 104, 20007–20012.
- Chang, S., Khoo, C.M., Naylor, M.L., Maser, R.S., and DePinho, R.A. (2003). Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. *Genes Dev.* 17, 88–100.
- Chang, Y.M., Kung, H.J., and Evans, C.P. (2007). Nonreceptor tyrosine kinases in prostate cancer. *Neoplasia* 9, 90–100.
- Chen, Z., Trotman, L.C., Shaffer, D., Lin, H.K., Dotan, Z.A., Niki, M., Koutcher, J.A., Scher, H.I., Ludwig, T., Gerald, W., et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature* 436, 725–730.
- Chin, K., de Solorzano, C.O., Knowles, D., Jones, A., Chou, W., Rodriguez, E.G., Kuo, W.L., Ljung, B.M., Chew, K., Myambo, K., et al. (2004). In situ analyses of genome instability in breast cancer. *Nat. Genet.* 36, 984–988.
- Chin, L., Artandi, S.E., Shen, Q., Tam, A., Lee, S.L., Gottlieb, G.J., Greider, C.W., and DePinho, R.A. (1999). p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. *Cell* 97, 527–538.
- d'Adda di Fagnana, F., Reaper, P.M., Clay-Farrace, L., Fiegler, H., Carr, P., Von Zglinicki, T., Saretzki, G., Carter, N.P., and Jackson, S.P. (2003). A DNA damage checkpoint response in telomere-initiated senescence. *Nature* 426, 194–198.
- DePinho, R.A. (2000). The age of cancer. *Nature* 408, 248–254.
- Ding, Z., Wu, C.J., Chu, G.C., Xiao, Y., Ho, D., Zhang, J., Perry, S.R., Labrot, E.S., Wu, X., Lis, R., et al. (2011). SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. *Nature* 470, 269–273.
- Emmert-Buck, M.R., Bonner, R.F., Smith, P.D., Chuaqui, R.F., Zhuang, Z., Goldstein, S.R., Weiss, R.A., and Liotta, L.A. (1996). Laser capture microdissection. *Science* 274, 998–1001.
- Farazi, P.A., Glickman, J., Horner, J., and Depinho, R.A. (2006). Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. *Cancer Res.* 66, 4766–4773.
- Feldmann, G., Beaty, R., Hruban, R.H., and Maitra, A. (2007). Molecular genetics of pancreatic intraepithelial neoplasia. *J. Hepatobiliary Pancreat. Surg.* 14, 224–232.
- Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011). COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res.* 39(Database issue), D945–D950.
- González-Suárez, E., Samper, E., Flores, J.M., and Blasco, M.A. (2000). Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. *Nat. Genet.* 26, 114–117.
- Guo, Y., Sklar, G.N., Borkowski, A., and Kyprianou, N. (1997). Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. *Clin. Cancer Res.* 3, 2269–2274.
- Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks, M.W., and Weinberg, R.A. (1999). Creation of human tumour cells with defined genetic elements. *Nature* 400, 464–468.
- Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004). Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. *Am. J. Pathol.* 164, 217–227.
- Hu, G., Chong, R.A., Yang, Q., Wei, Y., Blanco, M.A., Li, F., Reiss, M., Au, J.L., Haffty, B.G., and Kang, Y. (2009). MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. *Cancer Cell* 15, 9–20.
- Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. *CA Cancer J. Clin.* 60, 277–300.
- Jenkins, R.B., Qian, J., Lieber, M.M., and Bostwick, D.G. (1997). Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. *Cancer Res.* 57, 524–531.
- Johnson, T.R., Khandrika, L., Kumar, B., Venezia, S., Koul, S., Chandhoke, R., Maroni, P., Donohue, R., Meacham, R.B., and Koul, H.K. (2008). Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer. *Mol. Cancer Res.* 6, 1639–1648.
- Kallakury, B.V., Brien, T.P., Lowry, C.V., Muraca, P.J., Fisher, H.A., Kaufman, R.P., Jr., and Ross, J.S. (1997). Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas. *Diagn. Mol. Pathol.* 6, 192–198.
- Kikuno, N., Shiina, H., Urakami, S., Kawamoto, K., Hirata, H., Tanaka, Y., Place, R.F., Pookot, D., Majid, S., Igawa, M., and Dahiya, R. (2007). Knock-down of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. *Oncogene* 26, 7647–7655.
- Kim, M., Gans, J.D., Nogueira, C., Wang, A., Paik, J.H., Feng, B., Brennan, C., Hahn, W.C., Cordon-Cardo, C., Wagner, S.N., et al. (2006). Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. *Cell* 125, 1269–1281.
- Koeneman, K.S., Pan, C.X., Jin, J.K., Pyle, J.M., 3rd, Flanigan, R.C., Shankey, T.V., and Diaz, M.O. (1998). Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). *J. Urol.* 160, 1533–1539.
- Lapointe, J., Li, C., Higgins, J.P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U., et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. *Proc. Natl. Acad. Sci. USA* 101, 811–816.
- LaTulippe, E., Satagopan, J., Smith, A., Scher, H., Scardino, P., Reuter, V., and Gerald, W.L. (2002). Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. *Cancer Res.* 62, 4499–4506.
- Lee, H.W., Blasco, M.A., Gottlieb, G.J., Horner, J.W., 2nd, Greider, C.W., and DePinho, R.A. (1998). Essential role of mouse telomerase in highly proliferative organs. *Nature* 392, 569–574.
- Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliareis, C., Rodgers, L., McCombie, R., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 275, 1943–1947.
- Lin, Y., Uemura, H., Fujinami, K., Hosaka, M., Harada, M., and Kubota, Y. (1997). Telomerase activity in primary prostate cancer. *J. Urol.* 157, 1161–1165.
- Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J., and Berns, A. (2000). Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. *Genes Dev.* 14, 994–1004.
- Maser, R.S., Choudhury, B., Campbell, P.J., Feng, B., Wong, K.K., Protopopov, A., O'Neil, J., Gutierrez, A., Ivanova, E., Perna, I., et al. (2007). Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. *Nature* 447, 966–971.
- Meeker, A.K., Hicks, J.L., Platz, E.A., March, G.E., Bennett, C.J., Delannoy, M.J., and De Marzo, A.M. (2002). Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. *Cancer Res.* 62, 6405–6409.
- O'Hagan, R.C., Chang, S., Maser, R.S., Mohan, R., Artandi, S.E., Chin, L., and DePinho, R.A. (2002). Telomere dysfunction provokes regional amplification and deletion in cancer genomes. *Cancer Cell* 2, 149–155.
- Ongenaert, M., Van Neste, L., De Meyer, T., Menschaert, G., Bekaert, S., and Van Criekinge, W. (2008). PubMeth: a cancer methylation database

- combining text-mining and expert annotation. *Nucleic Acids Res.* 36 (Data-base issue), D842–D846.
- Rubin, M.A. (2008). Targeted therapy of cancer: new roles for pathologists—prostate cancer. *Mod. Pathol.* 21 (Suppl 2), S44–S55.
- Rudolph, K.L., Millard, M., Bosenberg, M.W., and DePinho, R.A. (2001). Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. *Nat. Genet.* 28, 155–159.
- Shay, J.W., and Wright, W.E. (2006). Telomerase therapeutics for cancer: challenges and new directions. *Nat. Rev. Drug Discov.* 5, 577–584.
- Sommerfeld, H.J., Meeker, A.K., Piatyszek, M.A., Bova, G.S., Shay, J.W., and Coffey, D.S. (1996). Telomerase activity: a prevalent marker of malignant human prostate tissue. *Cancer Res.* 56, 218–222.
- Storchova, Z., and Pellman, D. (2004). From polyploidy to aneuploidy, genome instability and cancer. *Nat. Rev. Mol. Cell Biol.* 5, 45–54.
- Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009). The cancer genome. *Nature* 458, 719–724.
- Takai, H., Smogorzewska, A., and de Lange, T. (2003). DNA damage foci at dysfunctional telomeres. *Curr. Biol.* 13, 1549–1556.
- Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., et al. (2010). Integrative genomic profiling of human prostate cancer. *Cancer Cell* 18, 11–22.
- Tomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 310, 644–648.
- Vanaja, D.K., Cheville, J.C., Iturria, S.J., and Young, C.Y. (2003). Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. *Cancer Res.* 63, 3877–3882.
- Varambally, S., Yu, J., Laxman, B., Rhodes, D.R., Mehra, R., Tomlins, S.A., Shah, R.B., Chandran, U., Monzon, F.A., Becich, M.J., et al. (2005). Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. *Cancer Cell* 8, 393–406.
- Vukovic, B., Park, P.C., Al-Maghrabi, J., Beheshti, B., Sweet, J., Evans, A., Trachtenberg, J., and Squire, J. (2003). Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. *Oncogene* 22, 1978–1987.
- Wu, X., Wu, J., Huang, J., Powell, W.C., Zhang, J., Matusik, R.J., Sangiorgi, F.O., Maxson, R.E., Sucov, H.M., and Roy-Burman, P. (2001). Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mech. Dev.* 101, 61–69.
- Yu, Y.P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., et al. (2004). Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. *J. Clin. Oncol.* 22, 2790–2799.
- Zender, L., Spector, M.S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.T., Luk, J.M., Wigler, M., Hannon, G.J., et al. (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. *Cell* 125, 1253–1267.
- Zhang, W., Kapusta, L.R., Slingerland, J.M., and Klotz, L.H. (1998). Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. *Cancer Res.* 58, 619–621.
- Zheng, H., Ying, H., Yan, H., Kimmelman, A.C., Hiller, D.J., Chen, A.J., Perry, S.R., Tonon, G., Chu, G.C., Ding, Z., et al. (2008). p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. *Nature* 455, 1129–1133.